KPRX Wutah pendapatan kuartal marang kuartal Kiora Pharmaceuticals Inc.

Simbol lan logo merek Kiora Pharmaceuticals, Inc. (KPRX)

Data on mid-phase trials for rare eye pathology drugs are expected, while the speculative price already prices in R&D risks. Kiora Pharmaceuticals (KPRX) revenues rely on government procurement and insurers for the treatment of genetic blindness. Analyzing the quarterly revenue growth trajectory in GURU.Markets, we note that the parameter has stabilized at 0.00, which is critical for the developer of KIO-301 photoswitches in the field of nano-ophthalmology.

KPRX (kiorapharma.com) riwayat Wutah pendapatan triwulanan saka 04.07.2022 nganti 20.11.2026

Rincian metrik komprehensif lan analitis Kiora Pharma (KPRX)

- kuotasi saiki lan rata-rata prakiraan nilai:
- data dhuwit lan arus kas:
Analisis umum perusahaan:Kiora Pharmaceuticals, Inc. (KPRX)
Produk seri Kiora Pharmaceuticals Inc.

Fundamental asset selection is based on an analysis of revenue growth rates, which allows for the assessment of market value through discounted cash flow analysis. This indicator measures the rate of change in quarterly revenue, reflecting the commercialization of Kiora Pharmaceuticals (KPRX) ophthalmology developments for the treatment of rare retinal pathologies, as clearly demonstrated by this quarterly revenue chart.